



New Horizons in Cancer Research: Delivering Cures Through Cancer Science

November 2-5, 2016 Shanghai Marriott Parkview Hotel Shanghai, P.R. China

Conference Co-Chairpersons José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY, USA Scott A. Armstrong, Dana-Farber Cancer Institute, Boston, MA, USA

Wednesday, November 2

15:30-17:45 Welcome and Keynote Addresses

Grand Ballroom 2-4

Welcome

Scott A. Armstrong, Dana-Farber Cancer Institute, Boston, MA, USA

Genomic-driven clinical studies in breast cancer

José Baselga, Memorial Sloan Kettering Cancer Center, New

York, NY, USA

The cell cycle mitotic regulator NIp in genomic instability

and tumorigenesis

Qimin Zhan, Chinese Academy of Medical Sciences, Beijing,

China

17:45-19:45 Opening Reception

Grand Ballroom 1 and Foyer.

Thursday, November 3

8:30-10:30 Session 1: Genomics, Targeted Therapies, and Clinical

Applications

Grand Ballroom 2-4

Chairperson: Nikhil Wagle, Dana-Farber Cancer Institute,

Boston, MA, USA

Precision medicine for metastatic breast cancer

Nikhil Wagle

Novel ways to target EGFR signaling in lung cancer

Christine M. Lovly, Vanderbilt University School of Medicine,

Nashville, TN, USA

How to design a clinical to	rial in Gl	cancer	based	on
precision medicine				

Rui-hua Xu, Sun Yat-sen University Cancer Center, Guangzhou, China

10:30-11:00 Tea Break

Grand Ballroom 1 and Grand Ballroom Foyer

11:00-13:00 Session 2: Epigenetic Mechanisms in Cancer Development

and Therapy Grand Ballroom 2-4 Chairperson:

Scott A. Armstrong, Dana-Farber Cancer Institute, Boston,

MA, USA

Histone methylation regulation, recognition and link to human diseases

Yang Shi, Boston Children's Hospital, Boston, MA, USA

Targeting epigenetic mechanisms in cancer

Scott A. Armstrong

Targeting non-coding RNA as a new paradigm in human glioma treatment

Yutaka Kondo, Nagoya City University Graduate School of

Medical Sciences, Nagoya, Japan

13:00-15:30 Poster Session A with Lunch

Ballroom 1-3

Clinical Research and Clinical Trials

Immunology Molecular Biology Tumor Biology

15:45-17:15 Professional Advancement Session: Getting Your Research

Published

Grand Ballroom 2-4

Presenter: José Baselga, Editor-in-Chief, Cancer Discovery

Friday, November 4

8:15-9:15 Keynote Address

Grand Ballroom 2-4

MicroRNAs as key regulators of homeostasis

David Baltimore, California Institute of Technology, Pasadena,

CA, USA

9:15-11:00 Session 3: Tumor Heterogeneity in Cancer Development and

Progression

Grand Ballroom 2-4

Chairperson: Luis F. Parada, Memorial Sloan Kettering

Cancer Center, New York, NY, USA

Intratumor heterogeneity of genomic alterations and clonal evolution in esophageal squamous cell carcinoma

Ming-Rong Wang, Peking Union Medical College, Beijing, China

The role of cell of origin and cancer stem cells in GBM phenotype

Luis F. Parada

11:00-11:30 **Tea Break**

Grand Ballroom 1 and Grand Ballroom Foyer

11:30-13:30 Session 4: Tumor Metabolism and Developmental Pathways

Grand Ballroom 2-4

Chairperson: Bin Tean Teh, National Cancer Center,

Singapore, Singapore

Hippo signaling in growth control and beyond

Duojia D.J. Pan, Howard Hughes Medical Institute, UT

Southwestern Medical Center, Dallas, TX, USA

The role of metabolism in cancer cachexia

Bin Tean Teh

Targeted inhibition of IDHm in cancer: The path to developing a new approach to AML treatment

Katharine Yen, Agios Pharmaceuticals, Inc., Cambridge, MA,

USA

13:30-16:00 Poster Session B with Lunch

Ballroom 1-3

Bioinformatics and Computational Biology

Cellular Biology

Chemistry

Epidemiology

Experimental Molecular Therapy

Prevention Research

Tumor Biology

16:00-18:00 Session 5: Immunotherapy: Targeting Immune Mechanisms

Grand Ballroom 2-4

Chairperson: Michel Sadelain, Memorial Sloan Kettering

Cancer Center, New York, NY, USA

From the clinic to the lab: Investigating immune responses to immune checkpoint therapies

Padmanee Sharma, The University of Texas MD Anderson

Cancer Center, Houston, TX, USA

CAR therapy beyond the CD19 paradigm

Michel Sadelain

Exploiting the functional interplay between the epigenome and host immune system to devise new cancer therapies

Ricky W. Johnstone, Peter MacCallum Cancer Center,

Melbourne, VIC, Australia

DAY 4 - Saturday, November 5

8:30-10:30 Session 6: Molecular Tumor Prevention: Early Detection

Grand Ballroom 2-4

Chairperson: Hongyang Wang, Eastern Hepatobiliary

Surgery Institute, Shanghai, China

Liquid biopsies and the early diagnosis of cancer

Luis A. Diaz, Johns Hopkins Kimmel Comprehensive Cancer

Center, Baltimore, MD, USA

Serum miRNAs as predictive and preventive biomarker in

hepatocellular carcinoma

Hongyang Wang

Exploiting exosome biology in the diagnosis and treatment

of pancreatic cancer

Raghu Kalluri, The University of Texas MD Anderson Cancer

Center, Houston, TX, USA

10:30-11:00 **Tea Break**

Grand Ballroom 1 and Grand Ballroom Foyer

11:00-12:20 Session 7: Novel Targeted Approaches to Cancer Therapy

Grand Ballroom 2-4

Chairperson: Jilong Yang, Tianjin Medical University Cancer

Hospital & Institute, Tianjin, China

The evolution of cancer in response to targeted therapies

Jeffrey A. Engelman, Novartis Institutes for BioMedical

Research, Cambridge, MA, USA

Targeted approaches to sarcoma: Translational medicine

and precision medicine in the sequencing era

Jilong Yang

12:20-12:40 Closing Remarks and Departure

Grand Ballroom 2-4